| 摘要 |
The present invention relates to the use of VEGF antagonists and a novel anti-alpha5beta1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-alpha5beta1 antibodies and methods of making and using them.
|
